Evaluation of the antigenotoxicity of polysaccharides and β-glucans from Agaricus blazei, a model study with the single cell gel electrophoresis/Hep G2 assay

Angeli, José Pedro Friedmann; Ribeiro, Lúcia Regina; Camelini, Carla Maísa; Mendonça, Margarida Matos de; Mantovani, Mário Sérgio

doi:10.1016/j.jfca.2009.03.003

Cited by 12 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Japan, beta-glucans-like lentinan and krestin (polysaccharide-K), isolated from certain medicinal mushrooms have been adjuncts to chemotherapy to treat cancers. A water-soluble protein-polysaccharide complex β-(1-6)-D-glucan, isolated from the fruiting bodies of Agaricus subrufescens (as A. blazei), showed immune-modulation activity (Angeli et al 2009). Lentinula edodes contains an active compound called lentinan.…”

Section: Revitalizing Skin and Anti-agingmentioning

confidence: 99%

“…net/en/products/Cosmetic_Ingredients_Protective_and_ Moisturizing.asp). There has been considerable research on the medicinal properties of Agaricus subrufescens (as A. blazei) and the protective affects of β-glucans (Firenzuoli et al 2008;Angeli et al 2009). This fungus has also been reported to have anti-mutagenic (Menoli et al 2001;Machado et al 2005, anti-clastogenic (Luiz et al 2003Matuo et al 2007), anti-genotoxic and anti-tumor affects (Mizuno et al 1990(Mizuno et al , 1999.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fungi—an unusual source for cosmetics

2010

View full text Add to dashboard Cite

Fruiting bodies of some wild and cultivatable mushrooms contain medicinal compounds which are being used in traditional medicines and cosmetics. There are numerous potential medicinal products from mushrooms that could be used in cosmeceuticals (products applied topically, such as creams, lotions, and ointments) or nutricosmetics (products that are ingested orally). This paper provides a review of the fungi presently used in cosmeceuticals and nutricosmetics with some examples of cosmetic types and products. Species presently used, or patented to be used, in cosmeceuticals and nutricosmetics include Agaricus subrufescens (= A. blazei, A. brasiliensis) Choiromyces maeandriformis Cordyceps sinensis, Ganoderma lucidum, Grifola frondosa, Hypsizygus ulmarium, Inonotus obliquus, Lentinula edodes, Polyporus spp., Trametes versicolor, Tremella fuciformis, Tuber spp., Schizophyllum commune and many other lesser used taxa. Cosmetics incorporating fungi include those for skin care such as anti-aging, anti-oxidants, skin revitalizing, skin whitening and hair products. The mushrooms presently used are traditionally known to produce medicinal compounds and thus were the first to be incorporated in cosmetic applications. There are, however, numerous other mushroom species that are untested, undescribed or not yet cultivatable and that have huge potential for use in the cosmetic industry. Some fungi are also used in biotransformation and the products such as lactic acid and ceramides could potentially be used in cosmetics.

show abstract

Section: Revitalizing Skin and Anti-agingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Fungi—an unusual source for cosmetics

2010

View full text Add to dashboard Cite

show abstract

“…A. subrufescens Peck) is a Brazilian mushroom closely related to A. blazei Murrill (sensu Heinemann). In vitro and in vivo studies have shown mainly immunomodulatory [3,4,5], antitumoral [6], antigenotoxic [7], and antioxidant [3] activities for polysaccharides isolated from A. brasiliensis fruiting bodies and mycelia.…”

Section: Introductionmentioning

confidence: 99%

Antiherpetic Mechanism of a Sulfated Derivative of <b><i>Agaricus brasiliensis</i></b> Fruiting Bodies Polysaccharide

Sousa

Camelini

Leal³

et al. 2014

Intervirology

View full text Add to dashboard Cite

Objective: To study the anti-herpes simplex virus (HSV) activity of a (1→6)-(1→3)-β-D-glucan isolated from Agaricus brasiliensis fruiting bodies (FR) as well as its chemically sulfated derivative (FR-S). Methods: The antiherpetic activity and mechanism of action was studied by viral plaque assay applying different methodological strategies. Results: Although FR presented no in vitro antiherpetic action at 1 mg/ml, FR-S displayed promising anti-HSV-1 and anti-HSV-2 activities in both simultaneous and postinfection treatments, resulting in selectivity indices (CC₅₀/EC₅₀) higher than 393. FR-S had no virucidal effect, but significantly suppressed HSV-1 (EC₅₀ = 0.32 µg/ml) and HSV-2 (EC₅₀ = 0.10 µg/ml) adsorption. FR-S was less effective on adsorption inhibition of mutant virus strains devoid of gC (HSV-1 gC^-39 and HSV-2 gCneg1), indicating a possible interaction with this glycoprotein. The reduction of viral adsorption upon cell pretreatment with FR-S also suggests its interaction with cellular components. FR-S inhibited HSV-1 (EC₅₀ = 8.39 µg/ml) and HSV-2 (EC₅₀ = 2.86 µg/ml) penetration more efficiently than heparin. FR-S reduced HSV-1 and HSV-2 cell-to-cell spread. A synergic effect between FR-S and acyclovir was also detected. Conclusions: FR-S displays an interesting mechanism of antiviral action and represents a promising candidate for the treatment and/or prevention of herpetic infections, to be used as a single therapeutic agent or in combination with acyclovir.

show abstract